Rubius Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Rubius Therapeutics's estimated annual revenue is currently $13.2M per year.(i)
  • Rubius Therapeutics received $100.0M in venture funding in March 2018.
  • Rubius Therapeutics's estimated revenue per employee is $365,972
  • Rubius Therapeutics's total funding is $445M.
  • Rubius Therapeutics's current valuation is $792.6M. (January 2022)

Employee Data

  • Rubius Therapeutics has 36 Employees.(i)
  • Rubius Therapeutics grew their employee count by -28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities - cellular shielding, potent cell-cell interaction and tolerance induction. We plan to file our first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. We are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond. The company, a 2017 Fierce 15 award winner, was founded in 2013, is based in Cambridge, MA and is currently expanding across the all functions within the organization. Having completed our an initial public offering (Nasdaq: RUBY), we are well capitalized to execute our vision and strategy. For more information, please visit us at or follow us on Twitter.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Rubius Therapeutics's People

Director, Contracts AdministrationReveal Email/Phone
Assoc. Director, CMC Project ManagementReveal Email/Phone
ScientistReveal Email/Phone
Director, Preclinical DevelopmentReveal Email/Phone
VP, Program Management and Strategic OperationsReveal Email/Phone
Manager, Quality Control MicrobiologyReveal Email/Phone
VP Regulatory AffairsReveal Email/Phone
Associate Director Data ManagementReveal Email/Phone
VP, Platform and InnovationReveal Email/Phone
Chief Business OfficerReveal Email/Phone

Rubius Therapeutics News

2022-04-13 - Rubius Therapeutics Down 24%

By Josh Beckerman. Rubius Therapeutics Inc. shares were recently down 24% to $2.42 after multiple analysts lowered price targets on Monday.

2022-04-13 - Rubius Therapeutics Reports Updated Clinical Data at AACR ...

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The...

2022-04-06 - Rubius Therapeutics to Host Investor Webcast to Discuss ...

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company...

2021-11-09 - Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory Acute Myeloid ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Rubius Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-12-10$25.0MAFlagship VenturesArticle